SCHEMBL7251982

SCHEMBL7251982

COC(=O)c1cc(F)ccc1NC(=O)/C=C(/C)c1ccc2ccsc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.43
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38
PTGS1 P23219 1/20 0.37
KDM4E B2RXH2 4/20 0.37
MAPT P10636 3/20 0.37
LMNA P02545 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
MEN1 O00255 1/20 0.37
TNF P01375 1/20 0.37
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
NR2F2 P24468 1/20 0.37
HTT P42858 1/20 0.37
KMT2A Q03164 1/20 0.37
MCL1 Q07820 1/20 0.37
KLF5 Q13887 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025324 0.90 TERT (0.53) TERTALDH1A1CYP2C19LMNASMN1; SMN2
SCHEMBL7242175 0.87 TERT (0.56) TERTALDH1A1CYP1A2CYP2D6TSHR
SCHEMBL7251979 0.85 KDM4E (0.48) TERTALDH1A1KDM4EMAPTLMNA
SCHEMBL7241600 0.79 TERT (0.57) TERTALDH1A1CYP1A2CYP2D6TSHR
SCHEMBL4022703 0.78 TERT (0.71) TERTALDH1A1KDM4ELMNASMN1; SMN2
SCHEMBL7248045 0.78 TERT (0.41) TERTALDH1A1KDM4EMAPTLMNA
SCHEMBL4028328 0.77 TERT (0.49) TERTALDH1A1CYP1A2KDM4EMAPT
SCHEMBL6785402 0.74 TERT (0.60) TERTKDM4EMAPTSMN1; SMN2GAA
SCHEMBL4020296 0.72 TERT (0.77) TERTKDM4ELTB4R
SCHEMBL6782055 0.72 TERT (0.65) TERTALDH1A1TSHRKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6660764-B2 Telomerase inhibitors such as trans-3-(benzothien-6-yl)-but-2-enoic acid-N-(2-carboxy-phenyl)-amide; use as antitumor agent BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-12-09 US disclosed
US-20020123509-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-09-05 US disclosed
WO-2002051830-A1 CARBOXAMIDES FOR USE AS TELOMERASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123509-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and the preparation thereof ASS1, ADCY1, ADCY3 TERT 4749/4885ALDH1A1 59/4885CYP1A2 44/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.